David N. Gill

Insider Reports History

Entity
Individual
Location
C/O Nxstage Medical Inc. (Nxtm), 439 South Union Street, 5 Th Floor, Lawrence, MA
Signature
/s/ John LaRocca, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by David N. Gill:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Evolus, Inc. Director Common Stock 34K $428K $12.60 May 14, 2024 Direct
Y-mAbs Therapeutics, Inc. Director Common Stock 5.83K $69.9K $12.00 Jun 11, 2024 Direct
Y-mAbs Therapeutics, Inc. Director Employee Stock Option (right to buy) 14.5K Jun 11, 2024 Direct
Evolus, Inc. Director Stock Option (Right to Buy) 9.38K Feb 7, 2024 Direct
Strongbridge Biopharma plc Director Ordinary Shares 0 $2.06 Oct 5, 2021 Direct

Insider Reports Filed by David N. Gill

Symbol Company Period Transactions Value $ Form Type Date Filed Role
YMAB Y-mAbs Therapeutics, Inc. Jun 11, 2024 2 $0 4 Jun 13, 2024 Director
EOLS Evolus, Inc. May 13, 2024 2 -$131K 4 May 15, 2024 Director
EOLS Evolus, Inc. Feb 7, 2024 2 $0 4 Feb 9, 2024 Director
YMAB Y-mAbs Therapeutics, Inc. Jun 8, 2023 2 $0 4 Jun 9, 2023 Director
EOLS Evolus, Inc. Jan 27, 2023 2 $0 4 Jan 31, 2023 Director
YMAB Y-mAbs Therapeutics, Inc. Jul 15, 2022 1 $0 4 Jul 19, 2022 Director
EOLS Evolus, Inc. May 13, 2022 2 -$138K 4 May 17, 2022 Director
EOLS Evolus, Inc. Jan 24, 2022 2 $0 4 Jan 26, 2022 Director
SBBP Strongbridge Biopharma plc Oct 5, 2021 1 $0 4 Oct 6, 2021 Director
SBBP Strongbridge Biopharma plc Oct 1, 2021 1 -$36.6K 4 Oct 5, 2021 Director
YMAB Y-mAbs Therapeutics, Inc. Jun 10, 2021 1 $0 4 Jun 14, 2021 Director
SBBP Strongbridge Biopharma plc May 18, 2021 1 $0 4 May 18, 2021 Director
SBBP Strongbridge Biopharma plc May 14, 2021 1 -$44.8K 4 May 17, 2021 Director